Imagin Medical Inc. (IMEXF)

[lithiumjr]

https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aIME-2525843&symbol=IME®ion=C

Imagin Medical confirms that experts in the field of urology concur that one reason for the high recurrence rate after transurethral resection, is that some cancer not seen was left behind by the surgeon. Some years ago, enhanced cystoscopy was put forward as a way of identifying this unseen bladder cancer.

The uptake of enhanced cystoscopy has taken a number of years to evolve, partly because new equipment and supplies had to be purchased, as well as various procedural changes that needed to be implemented. But most significantly, many of these new procedures often require up to one hour for the physician to visualize the cancer and begin the cysto-TUR. Regardless of these impediments, enhanced cystoscopy is coming into the mainstream of treating bladder cancer. Imagin's i/Blue Imaging System is expected to reduce the time for physicians to visualize the cancer to 10 minutes.

In its recently published 2017 annual meeting highlights in bladder cancer, the American Urological Association stated, "... the benefits of enhanced cystoscopy were highlighted, particularly in terms of fluorescent cystoscopy, which improved cancer detection and improved recurrence-free survival." The conclusion is that the use of photo-dynamic diagnosis increases the detection of bladder cancer.

Jim Hutchens, president and chief executive officer of Imagin Medical, stated, "These procedures are an exciting, growing market in urology; and we believe our technology will continue the trend in enhanced cystoscopy."

About Imagin Medical Inc.

Imagin Medical is developing imaging solutions for minimally invasive surgical procedures where endoscopes are used. The company believes it will radically improve the way physicians detect cancer and view the surgical field. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth-most prevalent in the United States, and the most costly cancer to treat due to a greater than 50-per-cent recurrence rate.